All News

Article

EULAR 2025 – Day 3 Report

Jack Cush, MD Jun 13, 2025

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.

Article

EULAR 2025 – Day 2 Report

Jack Cush, MD Jun 12, 2025

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

Targets for OA pain pharmacotherapies some by the wayside: - NGF - TrkA but some very much in play and exciting: - neurotrophin-3 - TRPV1 - Nav1.7, 1.8 Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo

https://x.com/drdavidliew/status/1933842947922936060/photo/1

#TDM for #HCQ warns of #toxic #levels in #CRF v low GFR <30, <60, <90, >90 400mg/d all in low GFR toxic 200mg/d 25% in low GFR toxic 6mg/kg/d – low GFR is too ⬆️ adjust HCQ dose for pts with CRF POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE

#EULAR2025 Take Home message from Updated EULAR Recommendations @eular_org for #Lupus Nephritis: -Kidney Biopsy vital -Early use of Combination Therapies (HCQ + GC + Immunosuppressant + CNI/Belimumab/Obinutuzumab) -Severe: High dose Cyclo + GC @RheumNow https://t.co/jHFqdT1TLf

E3N cohort 78000+ women >30yrs follow up 698 incident RA cases) In non smokers, RA asso w/ -tall at birth HR=1.55 In smokers, RA risk associated w/ -prematurity HR=1.63 -in utero exposure to tobacco HR=1.83 (ns) #EULAR2025 @RheumNow POS0226 https://t.co/xC3k3kiKsZ

https://x.com/AurelieRheumo/status/1933566252582371485/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

What happens to the prevalence of D2T PsA if we use different parameters in its definition? Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)! OP0177 #EULAR2025 @rheumnow https://t.co/QbF15t3Zrz

https://x.com/Nellziade/status/1933270413477314604/photo/1

Maybe the pathogenesis gives us a clue on how to target things? Possibly the treatments which take down synovitis might not always help with nodules Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709

#EULAR2025 Abstr#POS0320 Data from TULIP+LTE compared to Lupus Toronto Cohort as Control showed Anifrolumab reduced organ damage progression up to 4 years vs real-world SOC in #SLE. Effect continued to 10yrs using novel extrapolate analysis @RheumNow https://t.co/bkjZCZ8xGr

https://x.com/Yuz6Yusof/status/1933491657250410888/photo/1

What kills in GCA? Greek national prospective cohort, small numbers and no doubt some channeling bias, but: Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality. With new options, all GCA pts should be on something #EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF

https://x.com/drdavidliew/status/1933511888719274282/photo/1

In PsA, can we better pick IL-17A inhibitor responders (after TNFi failure)? Transcriptomic profiling is going to get better at telling us which pathways are truly important for response to specific treatments POS0232 #EULAR2025 @RheumNow https://t.co/uycuXB0TFK

https://x.com/drdavidliew/status/1933512237257535958/photo/1

#digital #ulcers in #scleroderma🎯 Retrospective #iloprost vs #selexipag 👇 BIG advantage of oral #prostacyclin receptor #agonist vs iloprost healing faster ⬇️ulcers Selexipag used in iloprost failures; ⬇️IV access WOW! RCT needed #OP035 #EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0

https://x.com/Yuz6Yusof/status/1933198167765586162/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

cool stuff at #EULAR2025 RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in #RA w 1or >1 #bDMARD-IR N=242 D/C bDMARD, on #csDMARD #RA 12 yrs, 10SJC 12TJC 2.6 b/tsDMARD failure Wk12 EULAR good/mod response 61v 42% Sham▶️goes VNS ✅data= @RheumNow @eular_org abst#OP190

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

🦵🏼💉LOSEIT study: liraglutide led to slight↑ in medial joint space width in knee OA vs placebo (0.22 vs 0.07 mm), but difference not statistically significant (p=0.17). More potent GLP-1RAs may be needed for greater improvement in structural knee OA @RheumNow #EULAR2025 #OP0223

Topics

All News

EULAR 2025 – Day 3 Report

EULAR 2025 – Day 2 Report

Do you get our email newsletter?